ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Bladder Cancer Biologics Market Research Report 2024
Published Date: June 2024
|
Report Code: QYRE-Auto-18F17377
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Bladder Cancer Biologics Market Research Report 2024
BUY CHAPTERS

Global Bladder Cancer Biologics Market Research Report 2024

Code: QYRE-Auto-18F17377
Report
June 2024
Pages:90
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Vendors
Pfizer Inc
AstraZenenca
Bristol Myers Squibb Company
Chugai Pharmaceutical
Cold Genesys
Eli Lilly
Merck
Mirati Therapeutics
Roche Holding
Spectrum Pharmaceuticals
Taiho Pharmaceutical
Nighthawk Biosciences
OncoGenex

Bladder Cancer Biologics Market

The global Bladder Cancer Biologics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Bladder Cancer Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bladder Cancer Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bladder Cancer Biologics include AstraZenenca, Bristol-Myers Squibb Company, Chugai Pharmaceutical, Cold Genesys, Eli Lilly, Nighthawk Biosciences, Merck & Co, Mirati Therapeutics, OncoGenex, Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Bladder Cancer Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bladder Cancer Biologics.
The Bladder Cancer Biologics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Bladder Cancer Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bladder Cancer Biologics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Bladder Cancer Biologics Market Report

Report Metric Details
Report Name Bladder Cancer Biologics Market
Segment by Type
  • PD-1 Inhibitors
  • CTLA-4 Inhibitors
  • FGFR Inhibitors
  • Others
Segment by Application
  • Hospital
  • Specialty Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZenenca, Bristol-Myers Squibb Company, Chugai Pharmaceutical, Cold Genesys, Eli Lilly, Nighthawk Biosciences, Merck & Co, Mirati Therapeutics, OncoGenex, Pfizer, Roche Holding, Spectrum Pharmaceuticals, Taiho Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Bladder Cancer Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Bladder Cancer Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Bladder Cancer Biologics Market report?

Ans: The main players in the Bladder Cancer Biologics Market are AstraZenenca, Bristol-Myers Squibb Company, Chugai Pharmaceutical, Cold Genesys, Eli Lilly, Nighthawk Biosciences, Merck & Co, Mirati Therapeutics, OncoGenex, Pfizer, Roche Holding, Spectrum Pharmaceuticals, Taiho Pharmaceutical

What are the Application segmentation covered in the Bladder Cancer Biologics Market report?

Ans: The Applications covered in the Bladder Cancer Biologics Market report are Hospital, Specialty Clinic, Other

What are the Type segmentation covered in the Bladder Cancer Biologics Market report?

Ans: The Types covered in the Bladder Cancer Biologics Market report are PD-1 Inhibitors, CTLA-4 Inhibitors, FGFR Inhibitors, Others

1 Bladder Cancer Biologics Market Overview
1.1 Product Definition
1.2 Bladder Cancer Biologics by Type
1.2.1 Global Bladder Cancer Biologics Market Value Comparison by Type (2024-2030)
1.2.2 PD-1 Inhibitors
1.2.3 CTLA-4 Inhibitors
1.2.4 FGFR Inhibitors
1.2.5 Others
1.3 Bladder Cancer Biologics by Application
1.3.1 Global Bladder Cancer Biologics Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Other
1.4 Global Bladder Cancer Biologics Market Size Estimates and Forecasts
1.4.1 Global Bladder Cancer Biologics Revenue 2019-2030
1.4.2 Global Bladder Cancer Biologics Sales 2019-2030
1.4.3 Global Bladder Cancer Biologics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bladder Cancer Biologics Market Competition by Manufacturers
2.1 Global Bladder Cancer Biologics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bladder Cancer Biologics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bladder Cancer Biologics Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Bladder Cancer Biologics, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bladder Cancer Biologics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bladder Cancer Biologics, Product Type & Application
2.7 Global Key Manufacturers of Bladder Cancer Biologics, Date of Enter into This Industry
2.8 Global Bladder Cancer Biologics Market Competitive Situation and Trends
2.8.1 Global Bladder Cancer Biologics Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Bladder Cancer Biologics Players Market Share by Revenue
2.8.3 Global Bladder Cancer Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Bladder Cancer Biologics Market Scenario by Region
3.1 Global Bladder Cancer Biologics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bladder Cancer Biologics Sales by Region: 2019-2030
3.2.1 Global Bladder Cancer Biologics Sales by Region: 2019-2024
3.2.2 Global Bladder Cancer Biologics Sales by Region: 2025-2030
3.3 Global Bladder Cancer Biologics Revenue by Region: 2019-2030
3.3.1 Global Bladder Cancer Biologics Revenue by Region: 2019-2024
3.3.2 Global Bladder Cancer Biologics Revenue by Region: 2025-2030
3.4 North America Bladder Cancer Biologics Market Facts & Figures by Country
3.4.1 North America Bladder Cancer Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bladder Cancer Biologics Sales by Country (2019-2030)
3.4.3 North America Bladder Cancer Biologics Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bladder Cancer Biologics Market Facts & Figures by Country
3.5.1 Europe Bladder Cancer Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bladder Cancer Biologics Sales by Country (2019-2030)
3.5.3 Europe Bladder Cancer Biologics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bladder Cancer Biologics Market Facts & Figures by Region
3.6.1 Asia Pacific Bladder Cancer Biologics Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bladder Cancer Biologics Sales by Region (2019-2030)
3.6.3 Asia Pacific Bladder Cancer Biologics Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bladder Cancer Biologics Market Facts & Figures by Country
3.7.1 Latin America Bladder Cancer Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bladder Cancer Biologics Sales by Country (2019-2030)
3.7.3 Latin America Bladder Cancer Biologics Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bladder Cancer Biologics Market Facts & Figures by Country
3.8.1 Middle East and Africa Bladder Cancer Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bladder Cancer Biologics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bladder Cancer Biologics Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bladder Cancer Biologics Sales by Type (2019-2030)
4.1.1 Global Bladder Cancer Biologics Sales by Type (2019-2024)
4.1.2 Global Bladder Cancer Biologics Sales by Type (2025-2030)
4.1.3 Global Bladder Cancer Biologics Sales Market Share by Type (2019-2030)
4.2 Global Bladder Cancer Biologics Revenue by Type (2019-2030)
4.2.1 Global Bladder Cancer Biologics Revenue by Type (2019-2024)
4.2.2 Global Bladder Cancer Biologics Revenue by Type (2025-2030)
4.2.3 Global Bladder Cancer Biologics Revenue Market Share by Type (2019-2030)
4.3 Global Bladder Cancer Biologics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bladder Cancer Biologics Sales by Application (2019-2030)
5.1.1 Global Bladder Cancer Biologics Sales by Application (2019-2024)
5.1.2 Global Bladder Cancer Biologics Sales by Application (2025-2030)
5.1.3 Global Bladder Cancer Biologics Sales Market Share by Application (2019-2030)
5.2 Global Bladder Cancer Biologics Revenue by Application (2019-2030)
5.2.1 Global Bladder Cancer Biologics Revenue by Application (2019-2024)
5.2.2 Global Bladder Cancer Biologics Revenue by Application (2025-2030)
5.2.3 Global Bladder Cancer Biologics Revenue Market Share by Application (2019-2030)
5.3 Global Bladder Cancer Biologics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZenenca
6.1.1 AstraZenenca Company Information
6.1.2 AstraZenenca Description and Business Overview
6.1.3 AstraZenenca Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZenenca Bladder Cancer Biologics Product Portfolio
6.1.5 AstraZenenca Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Company Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bristol-Myers Squibb Company Bladder Cancer Biologics Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 Chugai Pharmaceutical
6.3.1 Chugai Pharmaceutical Company Information
6.3.2 Chugai Pharmaceutical Description and Business Overview
6.3.3 Chugai Pharmaceutical Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Chugai Pharmaceutical Bladder Cancer Biologics Product Portfolio
6.3.5 Chugai Pharmaceutical Recent Developments/Updates
6.4 Cold Genesys
6.4.1 Cold Genesys Company Information
6.4.2 Cold Genesys Description and Business Overview
6.4.3 Cold Genesys Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cold Genesys Bladder Cancer Biologics Product Portfolio
6.4.5 Cold Genesys Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Company Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Eli Lilly Bladder Cancer Biologics Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Nighthawk Biosciences
6.6.1 Nighthawk Biosciences Company Information
6.6.2 Nighthawk Biosciences Description and Business Overview
6.6.3 Nighthawk Biosciences Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Nighthawk Biosciences Bladder Cancer Biologics Product Portfolio
6.6.5 Nighthawk Biosciences Recent Developments/Updates
6.7 Merck & Co
6.7.1 Merck & Co Company Information
6.7.2 Merck & Co Description and Business Overview
6.7.3 Merck & Co Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Merck & Co Bladder Cancer Biologics Product Portfolio
6.7.5 Merck & Co Recent Developments/Updates
6.8 Mirati Therapeutics
6.8.1 Mirati Therapeutics Company Information
6.8.2 Mirati Therapeutics Description and Business Overview
6.8.3 Mirati Therapeutics Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Mirati Therapeutics Bladder Cancer Biologics Product Portfolio
6.8.5 Mirati Therapeutics Recent Developments/Updates
6.9 OncoGenex
6.9.1 OncoGenex Company Information
6.9.2 OncoGenex Description and Business Overview
6.9.3 OncoGenex Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 OncoGenex Bladder Cancer Biologics Product Portfolio
6.9.5 OncoGenex Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Company Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Pfizer Bladder Cancer Biologics Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
6.11 Roche Holding
6.11.1 Roche Holding Company Information
6.11.2 Roche Holding Description and Business Overview
6.11.3 Roche Holding Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Roche Holding Bladder Cancer Biologics Product Portfolio
6.11.5 Roche Holding Recent Developments/Updates
6.12 Spectrum Pharmaceuticals
6.12.1 Spectrum Pharmaceuticals Company Information
6.12.2 Spectrum Pharmaceuticals Description and Business Overview
6.12.3 Spectrum Pharmaceuticals Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Spectrum Pharmaceuticals Bladder Cancer Biologics Product Portfolio
6.12.5 Spectrum Pharmaceuticals Recent Developments/Updates
6.13 Taiho Pharmaceutical
6.13.1 Taiho Pharmaceutical Company Information
6.13.2 Taiho Pharmaceutical Description and Business Overview
6.13.3 Taiho Pharmaceutical Bladder Cancer Biologics Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Taiho Pharmaceutical Bladder Cancer Biologics Product Portfolio
6.13.5 Taiho Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bladder Cancer Biologics Industry Chain Analysis
7.2 Bladder Cancer Biologics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bladder Cancer Biologics Production Mode & Process
7.4 Bladder Cancer Biologics Sales and Marketing
7.4.1 Bladder Cancer Biologics Sales Channels
7.4.2 Bladder Cancer Biologics Distributors
7.5 Bladder Cancer Biologics Customers
8 Bladder Cancer Biologics Market Dynamics
8.1 Bladder Cancer Biologics Industry Trends
8.2 Bladder Cancer Biologics Market Drivers
8.3 Bladder Cancer Biologics Market Challenges
8.4 Bladder Cancer Biologics Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Vendors
Pfizer Inc
AstraZenenca
Bristol Myers Squibb Company
Chugai Pharmaceutical
Cold Genesys
Eli Lilly
Merck
Mirati Therapeutics
Roche Holding
Spectrum Pharmaceuticals
Taiho Pharmaceutical
Nighthawk Biosciences
OncoGenex
List of Tables
 Table 1. Global Bladder Cancer Biologics Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Bladder Cancer Biologics Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Bladder Cancer Biologics Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Bladder Cancer Biologics Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Bladder Cancer Biologics Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Bladder Cancer Biologics Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Bladder Cancer Biologics Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Bladder Cancer Biologics Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Bladder Cancer Biologics, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Bladder Cancer Biologics, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Bladder Cancer Biologics, Product Type & Application
 Table 12. Global Key Manufacturers of Bladder Cancer Biologics, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Bladder Cancer Biologics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bladder Cancer Biologics as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Bladder Cancer Biologics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Bladder Cancer Biologics Sales by Region (2019-2024) & (K Units)
 Table 18. Global Bladder Cancer Biologics Sales Market Share by Region (2019-2024)
 Table 19. Global Bladder Cancer Biologics Sales by Region (2025-2030) & (K Units)
 Table 20. Global Bladder Cancer Biologics Sales Market Share by Region (2025-2030)
 Table 21. Global Bladder Cancer Biologics Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Bladder Cancer Biologics Revenue Market Share by Region (2019-2024)
 Table 23. Global Bladder Cancer Biologics Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Bladder Cancer Biologics Revenue Market Share by Region (2025-2030)
 Table 25. North America Bladder Cancer Biologics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Bladder Cancer Biologics Sales by Country (2019-2024) & (K Units)
 Table 27. North America Bladder Cancer Biologics Sales by Country (2025-2030) & (K Units)
 Table 28. North America Bladder Cancer Biologics Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Bladder Cancer Biologics Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Bladder Cancer Biologics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Bladder Cancer Biologics Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Bladder Cancer Biologics Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Bladder Cancer Biologics Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Bladder Cancer Biologics Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Bladder Cancer Biologics Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Bladder Cancer Biologics Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Bladder Cancer Biologics Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Bladder Cancer Biologics Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Bladder Cancer Biologics Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Bladder Cancer Biologics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Bladder Cancer Biologics Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Bladder Cancer Biologics Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Bladder Cancer Biologics Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Bladder Cancer Biologics Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Bladder Cancer Biologics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Bladder Cancer Biologics Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Bladder Cancer Biologics Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Bladder Cancer Biologics Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Bladder Cancer Biologics Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Bladder Cancer Biologics Sales (K Units) by Type (2019-2024)
 Table 51. Global Bladder Cancer Biologics Sales (K Units) by Type (2025-2030)
 Table 52. Global Bladder Cancer Biologics Sales Market Share by Type (2019-2024)
 Table 53. Global Bladder Cancer Biologics Sales Market Share by Type (2025-2030)
 Table 54. Global Bladder Cancer Biologics Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Bladder Cancer Biologics Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Bladder Cancer Biologics Revenue Market Share by Type (2019-2024)
 Table 57. Global Bladder Cancer Biologics Revenue Market Share by Type (2025-2030)
 Table 58. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Bladder Cancer Biologics Sales (K Units) by Application (2019-2024)
 Table 61. Global Bladder Cancer Biologics Sales (K Units) by Application (2025-2030)
 Table 62. Global Bladder Cancer Biologics Sales Market Share by Application (2019-2024)
 Table 63. Global Bladder Cancer Biologics Sales Market Share by Application (2025-2030)
 Table 64. Global Bladder Cancer Biologics Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Bladder Cancer Biologics Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Bladder Cancer Biologics Revenue Market Share by Application (2019-2024)
 Table 67. Global Bladder Cancer Biologics Revenue Market Share by Application (2025-2030)
 Table 68. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2025-2030)
 Table 70. AstraZenenca Company Information
 Table 71. AstraZenenca Description and Business Overview
 Table 72. AstraZenenca Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. AstraZenenca Bladder Cancer Biologics Product
 Table 74. AstraZenenca Recent Developments/Updates
 Table 75. Bristol-Myers Squibb Company Company Information
 Table 76. Bristol-Myers Squibb Company Description and Business Overview
 Table 77. Bristol-Myers Squibb Company Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Bristol-Myers Squibb Company Bladder Cancer Biologics Product
 Table 79. Bristol-Myers Squibb Company Recent Developments/Updates
 Table 80. Chugai Pharmaceutical Company Information
 Table 81. Chugai Pharmaceutical Description and Business Overview
 Table 82. Chugai Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Chugai Pharmaceutical Bladder Cancer Biologics Product
 Table 84. Chugai Pharmaceutical Recent Developments/Updates
 Table 85. Cold Genesys Company Information
 Table 86. Cold Genesys Description and Business Overview
 Table 87. Cold Genesys Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Cold Genesys Bladder Cancer Biologics Product
 Table 89. Cold Genesys Recent Developments/Updates
 Table 90. Eli Lilly Company Information
 Table 91. Eli Lilly Description and Business Overview
 Table 92. Eli Lilly Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Eli Lilly Bladder Cancer Biologics Product
 Table 94. Eli Lilly Recent Developments/Updates
 Table 95. Nighthawk Biosciences Company Information
 Table 96. Nighthawk Biosciences Description and Business Overview
 Table 97. Nighthawk Biosciences Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Nighthawk Biosciences Bladder Cancer Biologics Product
 Table 99. Nighthawk Biosciences Recent Developments/Updates
 Table 100. Merck & Co Company Information
 Table 101. Merck & Co Description and Business Overview
 Table 102. Merck & Co Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Merck & Co Bladder Cancer Biologics Product
 Table 104. Merck & Co Recent Developments/Updates
 Table 105. Mirati Therapeutics Company Information
 Table 106. Mirati Therapeutics Description and Business Overview
 Table 107. Mirati Therapeutics Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Mirati Therapeutics Bladder Cancer Biologics Product
 Table 109. Mirati Therapeutics Recent Developments/Updates
 Table 110. OncoGenex Company Information
 Table 111. OncoGenex Description and Business Overview
 Table 112. OncoGenex Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. OncoGenex Bladder Cancer Biologics Product
 Table 114. OncoGenex Recent Developments/Updates
 Table 115. Pfizer Company Information
 Table 116. Pfizer Description and Business Overview
 Table 117. Pfizer Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Pfizer Bladder Cancer Biologics Product
 Table 119. Pfizer Recent Developments/Updates
 Table 120. Roche Holding Company Information
 Table 121. Roche Holding Description and Business Overview
 Table 122. Roche Holding Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Roche Holding Bladder Cancer Biologics Product
 Table 124. Roche Holding Recent Developments/Updates
 Table 125. Spectrum Pharmaceuticals Company Information
 Table 126. Spectrum Pharmaceuticals Description and Business Overview
 Table 127. Spectrum Pharmaceuticals Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Spectrum Pharmaceuticals Bladder Cancer Biologics Product
 Table 129. Spectrum Pharmaceuticals Recent Developments/Updates
 Table 130. Taiho Pharmaceutical Company Information
 Table 131. Taiho Pharmaceutical Description and Business Overview
 Table 132. Taiho Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Taiho Pharmaceutical Bladder Cancer Biologics Product
 Table 134. Taiho Pharmaceutical Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Bladder Cancer Biologics Distributors List
 Table 138. Bladder Cancer Biologics Customers List
 Table 139. Bladder Cancer Biologics Market Trends
 Table 140. Bladder Cancer Biologics Market Drivers
 Table 141. Bladder Cancer Biologics Market Challenges
 Table 142. Bladder Cancer Biologics Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Bladder Cancer Biologics
 Figure 2. Global Bladder Cancer Biologics Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Bladder Cancer Biologics Market Share by Type: 2023 & 2030
 Figure 4. PD-1 Inhibitors Product Picture
 Figure 5. CTLA-4 Inhibitors Product Picture
 Figure 6. FGFR Inhibitors Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Bladder Cancer Biologics Market Value by Application (2024-2030) & (US$ Million)
 Figure 9. Global Bladder Cancer Biologics Market Share by Application: 2023 & 2030
 Figure 10. Hospital
 Figure 11. Specialty Clinic
 Figure 12. Other
 Figure 13. Global Bladder Cancer Biologics Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 14. Global Bladder Cancer Biologics Market Size (2019-2030) & (US$ Million)
 Figure 15. Global Bladder Cancer Biologics Sales (2019-2030) & (K Units)
 Figure 16. Global Bladder Cancer Biologics Average Price (US$/Unit) & (2019-2030)
 Figure 17. Bladder Cancer Biologics Report Years Considered
 Figure 18. Bladder Cancer Biologics Sales Share by Manufacturers in 2023
 Figure 19. Global Bladder Cancer Biologics Revenue Share by Manufacturers in 2023
 Figure 20. Global 5 and 10 Largest Bladder Cancer Biologics Players: Market Share by Revenue in Bladder Cancer Biologics in 2023
 Figure 21. Bladder Cancer Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 22. Global Bladder Cancer Biologics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 23. North America Bladder Cancer Biologics Sales Market Share by Country (2019-2030)
 Figure 24. North America Bladder Cancer Biologics Revenue Market Share by Country (2019-2030)
 Figure 25. United States Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Canada Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 27. Europe Bladder Cancer Biologics Sales Market Share by Country (2019-2030)
 Figure 28. Europe Bladder Cancer Biologics Revenue Market Share by Country (2019-2030)
 Figure 29. Germany Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. France Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. U.K. Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Italy Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Russia Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. Asia Pacific Bladder Cancer Biologics Sales Market Share by Region (2019-2030)
 Figure 35. Asia Pacific Bladder Cancer Biologics Revenue Market Share by Region (2019-2030)
 Figure 36. China Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. Japan Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. South Korea Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. India Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Australia Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. China Taiwan Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Southeast Asia Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Latin America Bladder Cancer Biologics Sales Market Share by Country (2019-2030)
 Figure 44. Mexico Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Brazil Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Argentina Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Colombia Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Middle East and Africa Bladder Cancer Biologics Sales Market Share by Country (2019-2030)
 Figure 49. Middle East and Africa Bladder Cancer Biologics Revenue Market Share by Country (2019-2030)
 Figure 50. Turkey Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Saudi Arabia Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. UAE Bladder Cancer Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 53. Global Sales Market Share of Bladder Cancer Biologics by Type (2019-2030)
 Figure 54. Global Revenue Market Share of Bladder Cancer Biologics by Type (2019-2030)
 Figure 55. Global Bladder Cancer Biologics Price (US$/Unit) by Type (2019-2030)
 Figure 56. Global Sales Market Share of Bladder Cancer Biologics by Application (2019-2030)
 Figure 57. Global Revenue Market Share of Bladder Cancer Biologics by Application (2019-2030)
 Figure 58. Global Bladder Cancer Biologics Price (US$/Unit) by Application (2019-2030)
 Figure 59. Bladder Cancer Biologics Value Chain
 Figure 60. Bladder Cancer Biologics Production Process
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Global Non Muscle Invasive Bladder Cancer Treatment Market Research Report 2024
Bladder Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biologics Drug Discovery Market Research Report 2024
Global Soft Tissue Biologics Market Research Report 2024
Global Bladder Diseases Drug Market Research Report 2025
Global Respiratory Biologics Market Research Report 2024
Global Ophthalmic Biologics Market Research Report 2024
Global Biologics Drug Development Market Research Report 2024
Global Autologous Biologics Market Research Report 2025
Global Bladder Cancer Molecular Diagnostics Market Research Report 2024
Global Urinary Tract Cancer Treatment Market Research Report 2024
Global Biosimilar and Biologics Market Research Report 2024
Biologic Therapeutic Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Urological Cancer Therapeutics Drugs Market Research Report 2024
Global Urological Cancer Drugs Market Research Report 2024
Global Muscle Invasive Bladder Cancer Treatment Market Research Report 2024
Urinary Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Spinal Biologics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Urinary System Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions